Blue Bridge is a technology company.
Blue Bridge has raised $2.0M across 1 funding round.
Blue Bridge has raised $2.0M in total across 1 funding round.
Blue Bridge has raised $2.0M in total across 1 funding round.
Blue Bridge's investors include eFounders, IDInvest Partners, Partech Ventures, Alexandre Dalyac, Didier Valet.
BlueBridge Technologies is a digital health technology company specializing in software and systems for connected medical devices, digital therapeutics, diagnostics, and patient-to-cloud platforms, primarily serving medtech, biopharma, and healthcare providers to manage chronic conditions like cancer, diabetes, Parkinson's, respiratory, and heart disease.[4][2][3] Its solutions streamline clinical trials, patient digitization, disease progression assessment using patient data, and integration with healthcare systems, enabling better outcomes for patients and providers.[3][1][4] Note: Search results identify two distinct entities—"BlueBridge Technologies" (Ireland-based, founded 2006, acquired by Everfield in 2022) focused on medtech innovation, and "Blue Bridge Technologies" (Latvia-based, founded 2007) offering practice management like SmartMedical for 370+ Latvian institutions; this overview centers on the more prominent Irish firm given query phrasing and result depth, with Latvian distinctions noted where relevant.[1][2][4]
BlueBridge Technologies was founded in 2006 in Dublin, Ireland, by a team of multi-skilled specialists in software, hardware, data science, cybersecurity, regulatory affairs, and quality, drawing from Silicon Valley tech, regulated finance, and manufacturing backgrounds.[2][4] The company emerged to address the need for intelligent components in connected medical-device ecosystems, anticipating that modern devices would require "brains" for managing chronic diseases.[4] Key milestones include developing the Respr device for Covid-19 monitoring with satellite data integration (supported by European Space Agency), participation in MDIC for SaMD threat modeling best practices, and acquisition by Everfield (financial acquisition, alive stage).[2][4] This evolution positioned it as a leader in digital health for life sciences, expanding from device software to end-to-end patient-to-cloud platforms.[3]
BlueBridge rides the wave of digital health transformation, particularly connected medical devices and patient-centric digitization amid rising chronic disease prevalence and demand for remote monitoring post-Covid.[2][4][3] Timing aligns with regulatory pushes for SaMD security, AI-driven diagnostics, and cloud integration in medtech/biopharma, amplified by initiatives like ESA collaborations and MDIC standards.[2][4] Market forces favoring it include aging populations, telemedicine growth, and biopharma's need for efficient clinical trials, positioning BlueBridge to influence ecosystems by enabling data-driven devices that improve outcomes and reduce workloads—e.g., via tools like Respr for real-time pandemic tracking.[2][1][3] Its Everfield backing expands global reach, accelerating adoption in life sciences.[2]
BlueBridge is poised for expansion in AI-enhanced digital therapeutics and secure connected devices, leveraging R&D investments and multidisciplinary expertise to capture medtech/biopharma demand amid trends like personalized medicine and cybersecurity mandates.[3][4] Expect deeper integration with wearables/IoT for chronic care, potential new ESA/pharma partnerships, and scaled patient-to-cloud platforms post-Everfield acquisition, evolving its influence from innovator to ecosystem enabler in a $500B+ digital health market.[2][3] As healthcare digitizes further, BlueBridge's regulated agility will drive pivotal impact, streamlining operations from patient intake to insurer settlements much like its Latvian tools already do at scale.[1][4]
Blue Bridge has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2025 | $2.0M Seed | eFounders, IDInvest Partners, Partech Ventures, Alexandre Dalyac, Didier Valet |